9 February 2026 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice on three medicines.

Donanemab (Kisunla) was not recommended to treat the early stages of Alzheimer’s disease in adults who carry one or no copies of a gene called ApoE4.

Read SMC press release